Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) CEO Johan M. Spoor bought 22,026 shares of the stock in a transaction dated Friday, March 28th. The stock was bought at an average price of $2.24 per share, with a total value of $49,338.24. Following the purchase, the chief executive officer now owns 59,383 shares of the company's stock, valued at approximately $133,017.92. This represents a 58.96 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Perspective Therapeutics Price Performance
CATX stock opened at $1.96 on Wednesday. The stock's 50 day simple moving average is $2.88 and its 200 day simple moving average is $6.10. Perspective Therapeutics, Inc. has a 12-month low of $1.90 and a 12-month high of $19.05.
Institutional Trading of Perspective Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC boosted its holdings in shares of Perspective Therapeutics by 3,994.9% in the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company's stock valued at $73,489,000 after buying an additional 5,370,392 shares during the period. Millennium Management LLC acquired a new position in Perspective Therapeutics in the fourth quarter valued at approximately $4,132,000. State Street Corp grew its holdings in shares of Perspective Therapeutics by 119.6% during the third quarter. State Street Corp now owns 2,190,239 shares of the company's stock valued at $29,240,000 after purchasing an additional 1,192,812 shares during the last quarter. Octagon Capital Advisors LP raised its position in shares of Perspective Therapeutics by 62.1% during the 4th quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company's stock worth $7,352,000 after purchasing an additional 882,528 shares during the period. Finally, Affinity Asset Advisors LLC lifted its holdings in shares of Perspective Therapeutics by 160.0% in the 4th quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company's stock worth $4,147,000 after purchasing an additional 800,000 shares during the last quarter. 54.66% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several brokerages have issued reports on CATX. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a research report on Monday. Cantor Fitzgerald raised shares of Perspective Therapeutics to a "strong-buy" rating in a research note on Tuesday, March 4th. Brookline Capital Management raised shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Monday, March 10th. Wedbush reaffirmed an "outperform" rating and set a $11.00 target price on shares of Perspective Therapeutics in a research report on Wednesday, March 26th. Finally, Royal Bank of Canada reduced their price target on Perspective Therapeutics from $16.00 to $15.00 and set an "outperform" rating for the company in a report on Thursday, March 27th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $14.44.
View Our Latest Report on CATX
Perspective Therapeutics Company Profile
(
Get Free Report)
Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
